Clinical Trial: Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Multiple Myeloma
Study Type: INTERVENTIONAL
Official Title: ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES
Brief Summary:
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Read more